On Oct. 30, Eli Lilly will announce third-quarter earnings results that could lift the stock, or pressure it further. Here ...

Eli Lilly is poised to leapfrog Novo Nordisk and become the dominant player in an anti-obesity drug market that could reach ...

Several sources are speculating that the potential buyer could be Eli Lilly, despite the breakdown of the pharma's ...

Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

Shares of Novo Nordisk and Eli Lilly dropped sharply in early trading Friday after President Donald Trump said Thursday that ...

Lilly is looking to build four pharmaceutical plants across the country. Two announcements are in the works.

Eli Lilly (NYSE: LLY) has outperformed the market over the past 20 years by 5.81% on an annualized basis producing an average annual return of 14.88%. Currently, Eli Lilly has a market capitalization ...

Eli Lilly (NYSE: LLY) has been one of the best-performing healthcare giants over the past decade. It now stands as the ...

Eli Lilly holds the lead position in the weight management market right now. But Viking Therapeutics is working on a ...

President Trump said he would lower the prices of popular weight-loss drugs, pressuring shares of drugmakers Novo Nordisk and ...